Posted by Michael Wonder on 27 Mar 2017
Should we pay more to treat rare diseases?
22 March 2017 - The UK’s public health watchdog is pressing ahead with plans to introduce a “dynamic upper limit” to the price new orphan drugs recommended for use in the National Health Service can command.
The approach will introduce “a sliding scale, so that the more the medicine costs the greater the health benefit it must provide in order to be approved for routine use.”
The upper limit for orphan drugs will be £300,000 ($370,000) per quality-adjusted life year, triple the amount originally proposed by the National Institute for Health and Care Excellence.
